(VIANEWS) – CRISPR Therapeutics AG (CRSP), Argan (AGX), Catalyst Pharmaceuticals (CPRX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. CRISPR Therapeutics AG (CRSP)

500% sales growth and 25.41% return on equity

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.

CRISPR Therapeutics AG’s sales growth this year is anticipated to be 113760% and a negative 94% for next year.

Year-on-year quarterly revenue growth grew by 2046950%, now sitting on 901.76M for the twelve trailing months.

Volume

Today’s last reported volume for CRISPR Therapeutics AG is 1167070 which is 9.35% above its average volume of 1067220.

CRISPR Therapeutics AG’s sales growth for the next quarter is 500%. The company’s growth estimates for the current quarter and the next is a negative 31.8% and negative -19.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.41%.

Volatility

CRISPR Therapeutics AG’s last day, last week, and last month’s current volatility was 0.58%, 1.84%, and 2.12%, respectively.

CRISPR Therapeutics AG’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.17% (day), 3.60% (last week), and 3.84% (last month), respectively.

CRISPR Therapeutics AG’s Stock Yearly Top and Bottom Value

CRISPR Therapeutics AG’s stock is valued at $101.99 at 16:22 EST, way below its 52-week high of $220.20 and way higher than its 52-week low of $84.38.

CRISPR Therapeutics AG’s Moving Average

CRISPR Therapeutics AG’s worth is way under its 50-day moving average of $118.58 and way below its 200-day moving average of $122.93.

Previous days news about CRISPR Therapeutics AG(CRSP)

  • According to Bloomberg Quint on Wednesday, 6 October, "The CEO anticipates Vertex’s next product will be a gene-editing therapy it’s developing with CRISPR Therapeutics AG for sickle cell and other inherited blood disorders. "

2. Argan (AGX)

36.6% sales growth and 12.83% return on equity

Argan, Inc., through its subsidiaries, provides engineering, procurement, construction, commissioning, operations management, maintenance, project development, technical, and consulting services to the power generation and renewable energy markets.

Argan’s sales growth this year is anticipated to be 40% and 42.5% for next year.

Year-on-year quarterly revenue growth grew by 52%, now sitting on 503.92M for the twelve trailing months.

Volume

Today’s last reported volume for Argan is 38299 which is 32.4% below its average volume of 56663.

Argan’s sales growth is a negative 0% for the ongoing quarter and 36.6% for the next. The company’s growth estimates for the current quarter and the next is a negative 21.7% and 10%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.83%.

Volatility

Argan’s last day, last week, and last month’s current volatility was 0.66%, 1.09%, and 1.66%, respectively.

Argan’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.37% (day), 2.55% (last week), and 2.78% (last month), respectively.

Argan’s Stock Yearly Top and Bottom Value

Argan’s stock is valued at $44.21 at 16:22 EST, way below its 52-week high of $55.99 and way higher than its 52-week low of $40.03.

Argan’s Moving Average

Argan’s value is under its 50-day moving average of $44.90 and under its 200-day moving average of $47.61.

3. Catalyst Pharmaceuticals (CPRX)

15.6% sales growth and 49.72% return on equity

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Catalyst Pharmaceuticals’s sales growth this year is expected to be 14.1% and 20.3% for next year.

Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 126.9M for the twelve trailing months.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 659549 which is 23.21% below its average volume of 858904.

Catalyst Pharmaceuticals’s sales growth for the next quarter is 15.6%. The company’s growth estimates for the ongoing quarter and the next is a negative 75.6% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 49.72%.

Volatility

Catalyst Pharmaceuticals’s last day, last week, and last month’s current volatility was 3.32%, 7.62%, and 2.98%, respectively.

Catalyst Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.19% (day), 7.65% (last week), and 4.84% (last month), respectively.

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $6.34 at 16:22 EST, below its 52-week high of $6.60 and way higher than its 52-week low of $2.88.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s worth is way above its 50-day moving average of $5.31 and way higher than its 200-day moving average of $5.31.

4. Invesco (IVZ)

14.8% sales growth and 9.96% return on equity

Invesco Ltd.

Invesco’s sales growth this year is anticipated to be 17.4% and 5.8% for next year.

Year-on-year quarterly revenue growth grew by 21.3%, now sitting on 6.51B for the twelve trailing months.

Volume

Today’s last reported volume for Invesco is 1508690 which is 64.74% below its average volume of 4278850.

News about Invesco(IVZ) today

  • Invesco to stay 'firm and steadfast' in fight against zee board: open letter. According to today’s article on Bloomberg Quint, "Zee’s 40% stock price increase after our intentions became public demonstrates the frustration of Zee’s long-suffering investors and the appetite for change," Invesco said in the letter", "The letter makes it clear that Invesco will not support a deal with Sony India on such terms. "

Invesco’s sales growth for the next quarter is 14.8%. The company’s growth estimates for the ongoing quarter and the next is 39.6% and 11.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.96%.

Volatility

Invesco’s last day, last week, and last month’s current volatility was 1.36%, 1.76%, and 2.32%, respectively.

Invesco’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.65% (day), 3.47% (last week), and 3.29% (last month), respectively.

Invesco’s Stock Yearly Top and Bottom Value

Invesco’s stock is valued at $24.89 at 16:22 EST, way under its 52-week high of $29.71 and way higher than its 52-week low of $12.75.

Invesco’s Moving Average

Invesco’s worth is below its 50-day moving average of $24.92 and below its 200-day moving average of $26.02.

Previous days news about Invesco(IVZ)

  • According to Bloomberg Quint on Wednesday, 6 October, "Zee has already filed a law suit asking the Bombay High Court to declare illegal and invalid a notice by key investors Invesco Developing Markets Fund and OFI Global China Fund LLC calling for a meeting of shareholders. "
  • According to Benzinga on Thursday, 7 October, "Apart from fintech lender Affirm Holdings and videogame retailer GameStop, the other stocks trending on the forum include e-commerce company ContextLogic Inc. (NASDAQ:WISH), social media giant Facebook Inc. (NASDAQ:FB), electric vehicle maker Tesla Inc. (NASDAQ:TSLA) and exchange-traded fund Invesco QQQ Trust (NASDAQ:QQQ)."
  • Price to earnings ratio insights for invesco. According to Benzinga on Wednesday, 6 October, "In the current market session, Invesco Inc. (NYSE:IVZ) is trading at $24.92, after a 1.77% drop. "

5. SilverSun Technologies (SSNT)

13.2% sales growth and 8.66% return on equity

SilverSun Technologies, Inc. operates as a business application, technology, and consulting company.

SilverSun Technologies’s sales growth this year is anticipated to be 17.6% and 5.6% for next year.

Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 42.58M for the twelve trailing months.

Volume

Today’s last reported volume for SilverSun Technologies is 9024 which is 73.48% below its average volume of 34035.

SilverSun Technologies’s sales growth for the next quarter is 13.2%. The company’s growth estimates for the current quarter and the next is a negative 0% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.66%.

Volatility

SilverSun Technologies’s last day, last week, and last month’s current volatility was 1.66%, 2.05%, and 2.57%, respectively.

SilverSun Technologies’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.17% (day), 2.00% (last week), and 4.79% (last month), respectively.

SilverSun Technologies’s Stock Yearly Top and Bottom Value

SilverSun Technologies’s stock is valued at $6.13 at 16:22 EST, way under its 52-week high of $14.87 and way above its 52-week low of $2.62.

SilverSun Technologies’s Moving Average

SilverSun Technologies’s worth is below its 50-day moving average of $6.74 and way under its 200-day moving average of $7.81.

LEAVE A REPLY

Please enter your comment!
Please enter your name here